Drug Trial Radar · NCT05807971
Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Apr 6, 2023
Primary completion
Feb 8, 2024
Study completion Feb 8, 2024
Sponsor
- Lead sponsor
- Athos Therapeutics IncIndustry
- Sponsor type
- Industry
- Collaborators
- Syneos Health; Athos Therapeutics Australia Pty Ltd
- First posted
- Apr 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test the ATH-063 drug (single and multiple doses) in Healthy Subjects. The clinical trial aims to evaluate the below. 1. Safety of the drug 2. Tolerability of the drug 3. Pharmacokinetics (PK) (how the human body affects the drug) 4. Pharmacodynamics (PD) (how the drug affects the human body) This will be a single center, Phase 1, First-In-Human, Randomized, Double-Blind (neither the subjects nor the experimenters know which subjects are in the test and control groups), Placebo (a look-alike substance that contains no active drug) - Controlled Study.
Conditions
- Inflammatory Bowel Diseases
- Crohn Disease
- Ulcerative Colitis
- Autoimmune Diseases
Interventions
ATH-063Drug
12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.
PlaceboDrug
Identical capsule to the drug without the active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of ATH-063 following oral administration of single and multiple ascending doses in healthy participants.Time frame: SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.